Is FibroBiologics struggling financially?

Yes, by its own account. FibroBiologics told the SEC on 30 Apr 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Apr 2026

15/100

Critical

Sector: Biotech/Pharma
Market cap: $9.6M
Source filing: 10-Q 30 Apr 2026
Balance sheet: 30 Jun 2026

Cash runway

2months

If the burn speeds up

Empty by Aug 2026
3months

If it eases off

Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.5M

Cash burned over the last 12 months

$16.7M

What FibroBiologics told the SEC

…Unless and until such time that revenue and net income are generated, the Company will need to continue to raise additional capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient…

FibroBiologics, Inc., Form 10-Q, filed 30 Apr 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

33.5% share-count increase The company issued stock. Each share now owns 25.1% less of the business than a year ago, before any change in the price.
Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.

Cash runway

The runway math

What FibroBiologics told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt